Fulcrum Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on small-molecule therapies for genetically defined rare diseases and rare hematological disorders. Form 8-K reports cover operating results, financial condition, Regulation FD corporate presentations, clinical updates for pociredir in sickle cell disease, and material agreements, including license arrangements tied to development programs.
Proxy materials disclose board and governance matters, executive compensation, equity awards, shareholder voting items, and related ownership information. The filing record also documents capital-structure items such as common stock and inducement equity plans alongside public-company disclosures tied to drug development programs and collaboration agreements.
THERAPEUTICS, INC. reports that Nantahala Capital Management, LLC and two affiliated reporting persons together beneficially own 3,050,040 shares of Common Stock.
As of March 31, 2026 the filing states those shares represent 4.58% of the class. The filing lists shared voting and dispositive power over the 3,050,040 shares and notes Messrs. Wilmot B. Harkey and Daniel Mack are filing as control persons in respect of shares held by Nantahala. Signatures are dated May 15, 2026.
Fulcrum Therapeutics files Amendment No. 1 to a previously submitted Schedule 13G, reporting shared voting and dispositive power over 5,250,000 shares of Common Stock. The amendment states this equals 7.9% of the class based on 66,633,321 shares outstanding as of April 20, 2026, and attributes the holdings to TCG Crossover II, its general partner TCG Crossover GP II, and Chen Yu.
The filing clarifies ownership chains and disclaims group status; it amends the original statement filed September 20, 2024, and attaches the joint-filing agreement referenced in the original.
Fulcrum Therapeutics, Inc. director Joshua Lehrer-Graiwer received a grant of stock options covering 64,000 shares of common stock. The options have an exercise price of $8.08 per share and are scheduled to vest in equal monthly installments until April 23, 2029, subject to continued service.
Fulcrum Therapeutics, Inc. director Joshua Lehrer-Graiwer filed an initial ownership report indicating that he currently holds no company securities. The filing shows zero shares directly owned following the reported holding entry, meaning he reports no beneficial ownership of Fulcrum Therapeutics stock at this time.
Fulcrum Therapeutics, Inc. will hold a virtual 2026 annual meeting on June 24, 2026 at 9:00 a.m. Eastern, where stockholders will vote on electing three Class I directors, a non-binding advisory vote on executive compensation, and ratifying Ernst & Young LLP as auditor.
Stockholders of record at the close of business on April 27, 2026, when 66,633,321 shares of common stock were outstanding, may vote online, by phone, mail, or during the virtual meeting. In 2025, Fulcrum reported a net loss of $74.9 million and completed a public equity offering raising $164.2 million of net proceeds, while CEO Alex Sapir received total compensation of $3.25 million.
Fulcrum Therapeutics reports Q1 2026 results with a net loss of $18.9 million, slightly wider than the prior-year period. Research and development expense was $14.1 million and general and administrative expense was $8.1 million as the company advances its rare-disease pipeline.
Lead candidate pociredir in sickle cell disease showed encouraging 20 mg PIONEER cohort data: mean absolute HbF rose 12.2% to 19.3%, 58% of patients reached HbF ≥20%, hemoglobin increased 1.1 g/dL, and vaso-occlusive crises fell versus expected events, with a generally well-tolerated safety profile.
Fulcrum ended the quarter with $333.3 million in cash, cash equivalents, and marketable securities and projects this will fund operations into 2029, while it narrows focus on pociredir and core benign hematology programs and exits the CAMP4 bone marrow failure collaboration.
Fulcrum Therapeutics reported first quarter 2026 results and several corporate updates. The company ended the quarter with $333.3 million in cash, cash equivalents, and marketable securities and continues to expect its cash resources will fund operations into 2029. For the quarter ended March 31, 2026, Fulcrum recorded a net loss of $18.9 million, compared with $17.7 million a year earlier, as research and development expenses rose to $14.1 million and general and administrative expenses to $8.1 million.
Fulcrum highlighted positive Phase 1b PIONEER data for its lead sickle cell disease candidate pociredir, including robust fetal hemoglobin induction and improvements in markers of hemolysis and anemia, and plans a potential registration-enabling trial in the second half of 2026. The company also dosed the first patient in a long-term extension trial and maintained that pociredir has been generally well-tolerated with no treatment-related serious adverse events to date.
Strategically, Fulcrum terminated its July 2023 license agreement with CAMP4 Therapeutics covering a Diamond-Blackfan anemia program. Governance changes include appointing Josh Lehrer as an independent Class III director, with a stock option grant for 64,000 shares at $8.08 per share, and the planned retirement of chief financial officer Alan Musso, who will remain until a successor is named and then serve as a consultant to support an orderly transition.
Fulcrum Therapeutics Inc ownership disclosure: The Vanguard Group filed an Amendment No. 2 to a Schedule 13G/A reporting 0 shares beneficially owned and 0% of the common stock as of 03/13/2026. The filing explains an internal realignment that caused certain Vanguard subsidiaries to report separately.
Fulcrum Therapeutics reports another year of heavy investment as it advances pociredir, its lead pill for sickle cell disease, through early clinical development. The company remains unprofitable, posting a $74.9 million net loss in 2025 and an accumulated deficit of $594.3 million as of December 31, 2025.
Pociredir showed encouraging Phase 1b results at the 20 mg dose, with mean fetal hemoglobin rising from 7.1% to 19.3% at Week 12 and markers of hemolysis and anemia improving. Seven of 12 patients reached ≥20% fetal hemoglobin and 58% reported no vaso-occlusive crises during treatment. Fulcrum plans an End-of-Phase meeting with the FDA and aims to start a potential registration-enabling trial in the second half of 2026.